Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.

Oncotarget - 11 Apr 2017

Boros Angela, Lacroix Ludovic, Lacas Benjamin, Adam Julien, Pignon Jean-Pierre, Caramella Caroline, Planchard David, de Montpreville Vincent, Deutsch Eric, Levy Antonin, Besse Benjamin, Le Pechoux Cécile

Abstract excerpt

INTRODUCTION: Chemo-radiation is standard treatment in locally advanced non-small cell lung cancers (NSCLC). The prognostic value of mutations has been poorly explored in this population. RESULTS: Clinical data were collected from 190 patients and mutational profiles were obtained in 78 of them; 58 (74%) were males, 31 (40%) current smokers, 47/31 stage IIIA/IIIB and 40 (51%) adenocarcinoma. The following...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Databases, Factual

Share to Kaplan-Meier Estimate

Share to Lung Neoplasms

Share to Neoplasm Staging

Share to Proportional Hazards Models

Source

Open in PubMed Open full text

Identifiers

PMID: 28445990
DOI: 10.18632/oncotarget.15966
PMCID: PMC5421921

Genes

ALK
EGFR
BRAF
KRAS
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.PMID 28445990Read ↗

Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small-cell lung carcinoma.Semantic proximity Read ↗

Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.Semantic proximity Read ↗

Lung Adenocarcinoma: Next Generation Sequencing and Outcome in Regional Community Oncology SettingSemantic proximity Read ↗

Characteristics and prognosis of EGFR mutations in small cell lung cancer patients in the NGS era.Semantic proximity Read ↗

Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?Semantic proximity Read ↗

A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancer.Semantic proximity Read ↗

Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.Semantic proximity Read ↗

The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who recieved concurrent chemoradiotherapy.Semantic proximity Read ↗

Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario.Semantic proximity Read ↗

Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.Semantic proximity Read ↗

Genetic Alterations and Risk Factors for Recurrence in Patients with Non-Small Cell Lung Cancer Who Underwent Complete Surgical ResectionSemantic proximity Read ↗

Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.